Align Technology, Inc. (ALGN) Director Sells $1,600,000.00 in Stock

Align Technology, Inc. (ALGN) Director Sells $1,600,000.00 in Stock

Align Technology, Inc. (NASDAQ:ALGN) Director Joseph Lacob sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 14th. The shares were sold at an average price of $320.00, for a total value of $1,600,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Joseph Lacob also recently made the following trade(s):

On Thursday, February 28th, Joseph Lacob sold 20,000 shares of Align Technology stock. The shares were sold at an average price of $258.31, for a total value of $5,166,200.00.

Shares of Align Technology stock traded up $10.78 during midday trading on Thursday, reaching $330.87. 765,388 shares of the company’s stock traded hands, compared to its average volume of 1,355,342. The company has a market cap of $26.47 billion, a PE ratio of 67.25, a P/E/G ratio of 2.49 and a beta of 2.14. Align Technology, Inc. has a 12 month low of $177.93 and a 12 month high of $398.88.

Align Technology (NASDAQ:ALGN) last posted its quarterly earnings data on Wednesday, April 24th. The medical equipment provider reported $0.89 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.83 by $0.06. The business had revenue of $549.00 million during the quarter, compared to the consensus estimate of $532.16 million. Align Technology had a return on equity of 30.58% and a net margin of 18.10%. The firm’s quarterly revenue was up 25.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.17 earnings per share. On average, equities analysts predict that Align Technology, Inc. will post 5.33 EPS for the current year.

Several brokerages have weighed in on ALGN. BidaskClub upgraded Align Technology from a “hold” rating to a “buy” rating in a research report on Friday, April 26th. UBS Group set a $325.00 target price on Align Technology and gave the company a “hold” rating in a report on Friday, April 26th. Zacks Investment Research upgraded Align Technology from a “hold” rating to a “buy” rating and set a $333.00 target price for the company in a report on Friday, April 26th. Credit Suisse Group upped their target price on Align Technology from $305.00 to $316.00 and gave the company an “outperform” rating in a report on Thursday, April 25th. Finally, Barclays upped their target price on Align Technology from $335.00 to $355.00 and gave the company an “overweight” rating in a report on Thursday, April 25th. Two investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $340.07.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. raised its holdings in Align Technology by 4.4% in the first quarter. BlackRock Inc. now owns 7,239,770 shares of the medical equipment provider’s stock worth $2,058,482,000 after purchasing an additional 304,685 shares in the last quarter. Viking Global Investors LP raised its holdings in Align Technology by 220.1% in the first quarter. Viking Global Investors LP now owns 1,795,990 shares of the medical equipment provider’s stock worth $510,654,000 after purchasing an additional 1,234,890 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in Align Technology by 22.4% in the fourth quarter. Bank of New York Mellon Corp now owns 1,334,677 shares of the medical equipment provider’s stock worth $279,521,000 after purchasing an additional 244,095 shares in the last quarter. Geode Capital Management LLC raised its holdings in Align Technology by 11.6% in the first quarter. Geode Capital Management LLC now owns 1,180,339 shares of the medical equipment provider’s stock worth $335,093,000 after purchasing an additional 122,947 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its holdings in Align Technology by 68.9% in the first quarter. Goldman Sachs Group Inc. now owns 1,173,060 shares of the medical equipment provider’s stock worth $333,537,000 after purchasing an additional 478,597 shares in the last quarter. Institutional investors and hedge funds own 81.53% of the company’s stock.

About Align Technology

Align Technology, Inc, a medical device company, designs, manufactures, and markets Invisalign clear aligners and iTero intraoral scanners and services for orthodontics, and restorative and aesthetic dentistry worldwide. It operates in two segments, Clear Aligner; and Scanners and Services. The Clear Aligner segment consists of comprehensive products, including Invisalign Comprehensive treatment that addresses the orthodontic needs of teenage patients, such as compliance indicators and compensation for tooth eruption; Invisalign Assist treatment, which offers support to dental practitioners throughout the treatment process, including progress tracking; and Invisalign First Phase I and Invisalign First Comprehensive Phase II package for younger patients with early mixed dentition with a mixture of primary/baby and permanent teeth.

Read More: Intrinsic Value

Related posts

Leave a Comment

Align Technology, Inc. (ALGN) Director Sold $1,600,000.00 in Shares

Align Technology, Inc. (ALGN) Director Sold $1,600,000.00 in Shares

Align Technology, Inc. (NASDAQ:ALGN) Director Joseph Lacob sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 14th. The shares were sold at an average price of $320.00, for a total value of $1,600,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Joseph Lacob also recently made the following trade(s):

On Thursday, February 28th, Joseph Lacob sold 20,000 shares of Align Technology stock. The shares were sold at an average price of $258.31, for a total value of $5,166,200.00.

Shares of Align Technology stock traded up $10.78 during midday trading on Thursday, reaching $330.87. 765,388 shares of the company’s stock traded hands, compared to its average volume of 1,355,342. The company has a market cap of $26.47 billion, a PE ratio of 67.25, a P/E/G ratio of 2.49 and a beta of 2.14. Align Technology, Inc. has a 12 month low of $177.93 and a 12 month high of $398.88.

Align Technology (NASDAQ:ALGN) last posted its quarterly earnings data on Wednesday, April 24th. The medical equipment provider reported $0.89 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.83 by $0.06. The business had revenue of $549.00 million during the quarter, compared to the consensus estimate of $532.16 million. Align Technology had a return on equity of 30.58% and a net margin of 18.10%. The firm’s quarterly revenue was up 25.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.17 earnings per share. On average, equities analysts predict that Align Technology, Inc. will post 5.33 EPS for the current year.

Several brokerages have weighed in on ALGN. BidaskClub upgraded Align Technology from a “hold” rating to a “buy” rating in a research report on Friday, April 26th. UBS Group set a $325.00 target price on Align Technology and gave the company a “hold” rating in a report on Friday, April 26th. Zacks Investment Research upgraded Align Technology from a “hold” rating to a “buy” rating and set a $333.00 target price for the company in a report on Friday, April 26th. Credit Suisse Group upped their target price on Align Technology from $305.00 to $316.00 and gave the company an “outperform” rating in a report on Thursday, April 25th. Finally, Barclays upped their target price on Align Technology from $335.00 to $355.00 and gave the company an “overweight” rating in a report on Thursday, April 25th. Two investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $340.07.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. raised its holdings in Align Technology by 4.4% in the first quarter. BlackRock Inc. now owns 7,239,770 shares of the medical equipment provider’s stock worth $2,058,482,000 after purchasing an additional 304,685 shares in the last quarter. Viking Global Investors LP raised its holdings in Align Technology by 220.1% in the first quarter. Viking Global Investors LP now owns 1,795,990 shares of the medical equipment provider’s stock worth $510,654,000 after purchasing an additional 1,234,890 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in Align Technology by 22.4% in the fourth quarter. Bank of New York Mellon Corp now owns 1,334,677 shares of the medical equipment provider’s stock worth $279,521,000 after purchasing an additional 244,095 shares in the last quarter. Geode Capital Management LLC raised its holdings in Align Technology by 11.6% in the first quarter. Geode Capital Management LLC now owns 1,180,339 shares of the medical equipment provider’s stock worth $335,093,000 after purchasing an additional 122,947 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its holdings in Align Technology by 68.9% in the first quarter. Goldman Sachs Group Inc. now owns 1,173,060 shares of the medical equipment provider’s stock worth $333,537,000 after purchasing an additional 478,597 shares in the last quarter. Institutional investors and hedge funds own 81.53% of the company’s stock.

About Align Technology

Align Technology, Inc, a medical device company, designs, manufactures, and markets Invisalign clear aligners and iTero intraoral scanners and services for orthodontics, and restorative and aesthetic dentistry worldwide. It operates in two segments, Clear Aligner; and Scanners and Services. The Clear Aligner segment consists of comprehensive products, including Invisalign Comprehensive treatment that addresses the orthodontic needs of teenage patients, such as compliance indicators and compensation for tooth eruption; Invisalign Assist treatment, which offers support to dental practitioners throughout the treatment process, including progress tracking; and Invisalign First Phase I and Invisalign First Comprehensive Phase II package for younger patients with early mixed dentition with a mixture of primary/baby and permanent teeth.

Read More: Intrinsic Value

Related posts

Leave a Comment